Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer

Summary

Background: Taxane plays a key role in the treatment of breast cancer and taxane-induced peripheral neuropathy (TIPN) is a dose-limiting adverse effect leading to treatment discontinuation. Ganglioside-monosialic acid (GM1) functions as a neuroprotective factor. However, the effects of GM1 on TIPN in breast cancer patients remains unknown. Purpose: This randomized phase III trial is designed to evaluate the potential effects of GM1 for preventing TIPN in breast cancer patients.

Timeline

Start

2015-05

Primary completion

2016-11

Completion

2016-12

Drugs

Indications